Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN1908-1909 in Cat-Allergic Rhinitis
NCT04981717Phase 3Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) comparing REGN1908-1909 with Placebo (2 arms). Primary endpoint: Daily Combined Symptom and Medication Score. Started Jul 2021; status: terminated.
02
Drugs
freneslerbartmevonlerbart
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT04981717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04981717.